- PCR diagnostics
The service is temporarily suspended (there are no reagents).
The availability of reagents to clarify by phone of the registry of the department of obstetric immunohematology: +375 17 239-59-45
You can record a study by phone: 8 (017) 377-09-37 From 8:00 to 16:00 daily (lunch 13: 00-13: 30), except for weekends and holidays.
The cost is represented in Belarusian rubles.
Name of the service Unit of measurement Tariff without VAT The cost of supplies Total cost 1
2
3
4
5
6
PCR diagnosis of the Rhesus Factor of the fetus by mother's blood Study
24.26
119.32
143.58
The release of nucleic acids Primary processing of biological material *9.3.1.1.1. Selection of nucleic acids by manual method of GCT* Study
12.74
18.65
31.39
Laboratory diagnostics 1.4. Vienna 1.4. Blood sampling from vein (biochemical blood test, UAC) GCT* Study
0.83
1.22
2.05
1.5. Processing of venous blood to obtain plasma or serum (pregnant) GCT* Study
0.52
1.09
1.61
1. Separate operations 1.2. Registration (preliminary and final) of the material, patient’s passport data and research results in journals and banks or PC GCT* Study
0.62
0.53
1.15
Molecular biological studies Primary processing of biological material *9.4.1.1. High -quality definition of oncogenes, the study of their expression by the PCR method in real time GCT* Study
9.55
97.83
107.38
- Determination of antibodies (m, g) to Sars-Cov-2 in the blood
The cost is represented in Belarusian rubles.
Name of the service Unit of measurement Rate
No VATThe cost of supplies Total cost 1
2
3
4
5
6
Laboratory diagnostics 1. 2. Registration (preliminary and final) of the material, patient’s passport data and research results in journals and banks or PCs* Study
0.59
0.50
1.09
1. 2. 1. Registration (provision of results by e -mail) Study
0.59
0
0.59
1. 4. * Blood sampling from a vein (biochemical blood test, UAC)* Study
0.77
1.98
2.75
1. 5. Celent blood processing to obtain plasma or serum* Study
0.46
0.02
0.48
8.17. 9. 1.26 Determination of antibodies (m, g) to Sars-Cov-2 in the blood Study
3.24
11.71
14.95
- Quantitative determination of IgG antibodies to the SARS-COV-2 virus for citizens of the Republic of Belarus
The cost is represented in Belarusian rubles.
Name of the service Unit of measurement Rate
No VATThe cost of supplies Total cost 1 2 3 4 5 6 2 ** Quantitative determination of IgG antibodies to the SARS-COV-2 virus Study 1.10 23.83 24.93 1. Separate operations 1. 2. * Registration (preliminary and final) of the material, patient’s passport data and research results in journals and banks or PCs* Registration 0.59 0.50 1.09 1. 2. 1. Registration (provision of results by e -mail)* Study 0.59 0 0.59 1.4. Vienna 1. 4. * Blood sampling from a vein (biochemical blood test, UAC)* Study 0.77 1.08 1.85 1. 5. Celent blood processing to obtain plasma or serum* Study 0.46 0.02 0.48 Total: 28.94 - Laboratory diagnostics for citizens of the Republic of Belarus
The cost is represented in Belarusian rubles.
Name of the service Unit of measurement Rate
No VAT
The cost of supplies Total cost 1 2 3 4 5 6 Laboratory diagnostics General clinical studies 3.1.6. Determination of osmotic resistance of red blood cells by the photometric method Study
14.11
5.59
19.70
Research Hemostasiogram (paragraphs 1.2. + 1.4.1. + 1.5. + 6.40.1. + 6.40.2. + 6.40.3. + 6.6.4.)* Study
3.01
30.99
34.00
Coprogram (paragraphs 1.2. + 2.8.1. + 2.8.2. + 2.8.3.) Study
4.31
7.95
12.26
General blood test with platelets (paragraphs 1.2.+ 1.4.+ 3.7.+ 3.9.1.+ 3.26.3.+ 3.6.1.)* Study
8.76
6.64
15.40
General blood test (paragraphs 1.2.+ 1.4 ..+ 3.7.+ 3.9.1.+ 3.26.3.) Study
5.96
6.10
12.06
General urine analysis (paragraphs 1. 2. +2. 1. 9. +2. 1. 4. 1. +2. 1.10. 1.)* Study
2.80
2.71
5.51
Determination of blood groups according to the system A on Cross-Cross, determination of the Rh factor (Clause 1.2.+P..1.4.2.+C.1.5.+Clause 7.2.)* Study
3.63
9.61
13.24
Rebraga test (paragraphs 1.2. + 1.4. + 1.5. + (5.13.3.1.3.) X2) Study
2.49
3.93
6.42
Screening test for determining syphilis (RPR-Carbon) (Clause 1.2.+ Clause 1.4.3.+ Clause 1.5.+ Clause 8.17.9.1.11) Study
5.40
7.22
12.62
1. Separate operations 1.1.2. Pipeting semi -automatic dispensers pipetting
0.04
0.07
0.11
1.1.3. Pipeting by automatic dispensers pipetting
0.01
0.07
0.08
1.2.* Registration (preliminary and final) of the material, patient’s passport data and research results in journals and banks or PCs* Registration
0.62
0.53
1.15
1.2.1. Registration (provision of results by e -mail)* Study
0.62
0
0.62
1.3. Blood from a finger 1.3.2. Taking blood from a finger for the entire spectrum of hematological studies in the concept of "general blood test", including a leukocyte formula Study
0.62
3.03
3.65
*1.3.1. Taking blood from a finger (antibodies) Study
0.26
1.08
1.34
1.4. Vienna Registration + processing of venous blood to obtain plasma or serum * Study
1.14
0.55
1.69
1.4.* Blood sampling from a vein (biochemical blood test, UAC)* Study
0.83
1.32
2.15
1.4.* Blood sampling from a vein (biochemical blood test, UAC) ** Study
0.83
1.32
2.15
1.4.* Blood fence from vein (biochemical blood test, UAC) *** Study
0.83
1.32
2.15
1.4.* Blood fence from vein (biochemical blood test, UAC) **** Study
0.83
1.32
2.15
1.4.1. Blood sampling from a vein (hemostasiogram, many and other separate indicators of a swelling system) Study
0.83
1.24
2.07
1.4.2. Blood fence from vein (blood type, Rh factor, antibodies) Study
0.83
2.19
3.02
1.4.3. Blood sampling from Vienna (immunochemistry, hormones, oncarkers, if (chlamydia, APS, autoimmune tests))* Study
0.83
1.24
2.07
1.4.3. Blood sampling from Vienna (immunochemistry, hormones, oncarkers, if (chlamydia, APS, autoimmune tests)) ** Study
0.83
1.24
2.07
1.4.4. Blood fence from vein (glycated hemoglobin, cardiodrica)) Study
0.83
1.24
2.07
1.5. Celent blood processing to obtain plasma or serum* Study
0.52
0.02
0.54
2.1. Urine research 2.1.2. Glucose detection with expess test in the urine Study
0.39
1.00
1.39
2.1.3.1. Detection of protein with an expess test in the urine Study
0.39
1.00
1.39
2.1.4.1. Determination of protein with sulfacylic acid in the urine* Study
1.04
0.42
1.46
2.1.6. Detection of ketone bodies with an express test in the urine Study
0.39
1.00
1.39
2.1.7. Detection of bilirubin with an express test in the urine Study
0.39
1.00
1.39
2.1.8. Detection of urobilin bodies with an express test in the urine Study
0.39
1.00
1.39
2.1.9. The study of the complex of parameters of general urine analysis by means of semi -automatic analyzers based on dry chemistry methods Study
0.52
1.21
1.73
2.1.10.1. Microscopic examination of sediment in the urine normally Study
0.62
0.55
1.17
2.1.11. Calculation of the number of uniform elements by Nechiporenko (urine analysis by Nechiporenko) Study
2.28
0.39
2.67
2.1.12. Determining the concentration ability of the kidneys by Zimnitsky Study
1.56
0.03
1.59
2.10. Detection of Trichomonas and Gonococci in the drugs of the separated genital organs painted with methylene blue according to gram 2.10.1. Detection of Trichomonas, gonococci in the drugs of the separated genitourinary organs painted with methylene blue (gynecol. Mais on the flora of 1 hearth)) Study
2.60
0.23
2.83
2.10.2. Detection of Trichomonas, Gonococci in the drugs of the separated genitourinary organs painted according to gram (gynecols. Mais on the flora of 1 hearth) Study
3.43
0.93
4.36
2.2. Study of spinal fluid 2.2.1. Determination of color, transparency, relative density, fibrous film in the cerebrospinal fluid Study
0.52
0.01
0.53
2.2.2. Detection of protein by reaction of Pandy in the cerebrospinal fluid Study
0.41
0.03
0.44
2.2.3.1. Determination of protein with sulfacylic acid in cerebrospinal fluid Study
0.93
0.10
1.03
2.2.4. Determination of the number of cellular elements (cytosis) and their differentiated calculation in the native drug in the cerebrospinal fluid Study
2.91
0.65
3.56
2.2.5. Microscopic examination in a painted drug in cerebrospinal fluid Study
2.39
0.77
3.16
2.3. Research of exudates and transfer 2.3.1. Determination of the number, character, color, transparency, relative density of exudants and Tansesuds Study
0.26
0.33
0.59
2.3.2. The detection of protein by reaction of the rivals of exudants and Tansesuds Study
0.65
0.56
1.21
2.3.3. Microscopic study Study
4.88
1.72
6.60
2.4. Sputum research 2.4.1. Determination of the number, character, color, consistency, smell in sputum Study
0.26
0.88
1.14
2.4.2.1. Microscopic examination of sputum in a native drug Study
1.32
1.18
2.50
2.4.2.2. Microscopic examination in sputum in a painted drug Study
1.56
0.57
2.13
2.4.3.2. Microscopy on acid-resistant microbacteria in the drugs painted according to cylies-nilsen. Study
3.43
1.26
4.69
2.7. The study of synovial fluid 2.7.1. Determination of physicochemical properties in synovial fluid Study
0.62
1.88
2.50
2.7.2. Microscopic examination with the calculation of the number of uniforms (cytosis) in the native drug in the synovial fluid Study
2.49
0.34
2.83
2.7.3. Microscopic examination in a painted drug in synovial fluid Study
1.87
0.90
2.77
2.8. Study of feces 2.8.1. Determination of color, consistency, smell, impurities, mucus, pH in feces Study
0.26
0.10
0.36
2.8.2. Detection of blood in the feces (AT to NB Human) Study
0.52
4.06
4.58
2.8.2.1. Bleeding test in feces (Lactoferin, Transferin, Calpropoxin) Study
0.52
48.06
48.58
2.8.3. Microscopic examination of feces (in 3 drugs) Study
2.91
3.26
6.17
2.8.4.1. Detection of protozoa in feces (cryptosporidia) Study
1.32
9.11
10.43
2.8.4.2. Detection of protozoa in feces (lamblia) Study
1.32
6.52
7.84
2.8.5. Helminthic detection by the CATO method (1 drug) in feces Study
1.66
0.36
2.02
2.9. Study of feces for enterobiosis 2.9.1. Study of scraping for enterobiosis (in 3 drugs) Study
1.66
1.11
2.77
3. Hematological studies 3.4. Counting reticulocytes in the blood* Study
2.08
2.21
4.29
3.5. Calculation of red blood cells with basophilic grain in the blood Study
2.39
0.54
2.93
3.6.1. Counting blood platelets in painted strokes by phonio Study
2.80
0.54
3.34
3.7. Determining the rate of erythrocyte in the blood (ESR) Study
0.26
1.91
2.17
3.9.1. Calculation of a leukocyte formula with a description of the morphology of blood cells for non -hemological diseases Study
1.97
0.54
2.51
3.13. Calculation of LE cells by Novoselova Study
9.36
2.44
11.80
3.14.1. Blood examination for malaria parasites with the preparation of a thick drop Study
3.84
1.48
5.32
3.14.2. Blood examination for malaria parasites in painted smear Study
3.32
1.48
4.80
3.26.3. Blood test using hematological analyzers of automatic, with differentiation of the leukocyte formula Study
2.28
1.80
4.08
5.10.1. Determination of cardiomarkers by dry chemistry 5.10.1.2. Troponin, Mioglobin, MV fraction of creative phosphokinase (quantitative definition of (simultaneous) cardiomarkers, dry chemistry method) Study
4.05
39.45
43.50
5.10.2. Determination of cardiomarkers by the immunochemical method 5.10.2.1. Troponin is ultra -sensitive in venous blood (determination of cardiomarkers by the immunochemical method) Study
4.36
13.63
17.99
5.10.2.2. Mioglobin in venous blood (determination of cardiomarkers by the immunochemical method)* Study
4.36
18.18
22.54
5.10.2.3. KFK-MW (concentration by mass) in venous blood (determination of cardiomarkers by the immunochemical method) Study
4.36
13.21
17.57
5.10.2.4. BNP (cerebral sodium peptide) in venous blood (determination of cardiomarkers by the immunochemical method) Study
4.36
43.61
47.97
5.10.2.5. NT-PROBNP (pro-brain sodium-reuretic peptide) in venous blood (determination of cardiomarkers by the immunochemical method)* Study
4.36
35.90
40.26
5.11.2. Determination of carcomorkers (oncomarkers) by immuno -function analysis, automated calculation 5.11.2.1. Alfa-phytoprotein (AFP) (determination of carcomorkers (oncomarkers) by immuno-function analysis, automated calculation)* Study
3.01
13.05
16.06
5.11.2.2. Chancerombreal antigen (KEA) (determination of carcomorkers (oncomarkers) by immuno -functional analysis, automated calculation* Study
3.01
13.38
16.39
5.11.2.3. CA 19-9 (determination of carcomorkers (oncomarkers) by immuno-function analysis, automated calculation)* Study
3.01
27.11
30.12
5.11.2.4. CA - 125 (determination of carcomorkers (oncomarkers) by immuno -function analysis, automated calculation)* Study
3.01
26.56
29.57
5.11.2.5. CA 15-3 (determination of carcomorkers (oncomarkers) by immunoeroferment analysis automated calculation)* Study
3.01
27.25
30.26
5.11.2.6. Prostatic antigen General (PSA) (determination of carcomorkers (oncomarkers) by immuno -functional analysis, automated calculation)* Study
3.01
14.73
17.74
5.11.2.7. Prostatic Antigen Free (St. PCA) (determination of carcomorkers (oncomarkers) by immuno -functional analysis, automated calculation)* Study
3.01
16.79
19.80
5.11.2.8. B-2-microglobulin Study
3.01
8.38
11.39
5.11.2.9. CA 242* Study
3.01
13.98
16.99
5.11.2.10. Cyfra 21-1* Study
3.01
22.53
25.54
5.11.2.11. He-4* Study
3.01
28.84
31.85
5.11.2.12. Determination of calcitonin Study
3.01
08/15
18.09
5.13.3.1. Conducting research using multi -channel biochemical autoanizers with non -dummy registration of research results 5.13.1.1. Glycated hemoglobin (HB A1) (determination of the concentration of glycated hemoglobin)* Study
0.26
7.52
7.78
5.13.3.1.1 Total protein (biochemical blood test)* Study
0.26
0.34
0.60
5.13.3.1.2. Albumin (biochemical blood test)* Study
0.26
0.24
0.50
5.13.3.1.3. Creatinine (biochemical blood test)* Study
0.26
1.03
1.29
5.13.3.1.4. Urea (biochemical blood test)* Study
0.26
0.46
0.72
5.13.3.1.5. Uric acid (biochemical blood test)* Study
0.26
0.39
0.65
5.13.3.1.6. General cholesterol (biochemical blood test)* Study
0.26
0.47
0.73
5.13.3.1.7. High density cholesterol (HDL) (biochemical blood test)* Study
0.26
1.39
1.65
5.13.3.1.8. LDL cholesterol LDL (LDL) (biochemical blood test)* Study
0.26
3.80
4.06
5.13.3.1.9. Serum glucose (biochemical blood test)* Study
0.26
0.16
0.42
5.13.3.1.10. General bilirubin (biochemical blood test)* Study
0.26
0.21
0.47
5.13.3.1.11. Direct bilirubin (biochemical blood test)* Study
0.26
0.36
0.62
5.13.3.1.13. Calcium (biochemical blood test)* Study
0.26
0.45
0.71
5.13.3.1.14 Potassium (biochemical blood test)* Study
0.26
0.99
1.25
5.13.3.1.15 Sodium (biochemical blood test)* Study
0.26
0.99
1.25
5.13.3.1.16 Chlorides (biochemical blood test)* Study
0.26
0.99
1.25
5.13.3.1.17 Phosphorus inorganic (biochemical blood test)* Study
0.26
0.20
0.46
5.13.3.1.18 Alaninaminotransferase ALT (biochemical blood test)* Study
0.26
0.31
0.57
5.13.3.1.19 AST ASPAPATAMINTRESSFERASE (Biochemical Blood Analysis)* Study
0.26
0.33
0.59
5.13.3.1.20 Alpha-amylase in blood serum (biochemical blood test)* Study
0.26
0.99
1.25
5.13.3.1.22 Pancreatic amylase (biochemical blood test)* Study
0.26
4.75
5.01
5.13.3.1.23 Lipaza* Study
0.26
1.24
1.50
5.13.3.1.24 Alkaline phosphatase (determination of activity) (biochemical blood test)* Study
0.26
0.40
0.66
5.13.3.1.25 Gamma-glutamintranspeptidase GGTP (determination of activity) (biochemical blood test)* Study
0.26
0.56
0.82
5.13.3.1.26 HBDH (determination of activity) (biochemical blood test)* Study
0.26
1.02
1.28
5.13.3.1.27 Lactate dehydrogenase LDH (determination of activity) (biochemical blood test)* Study
0.26
0.51
0.77
5.13.3.1.28 CFC creatine phosphokinase (determination of activity) (biochemical blood test)* Study
0.26
0.88
1.14
5.13.3.1.29 KFK-MV (determination of activity) (biochemical blood test)* Study
0.26
4.02
4.28
5.13.3.1.30 Serum iron in blood serum (level determination) (biochemical blood test)* Study
0.26
2.31
2.57
5.13.3.1.31 Triglycerides (biochemical blood test)* Study
0.26
0.96
1.22
5.13.3.1.32 Ferritin (biochemical blood test)* Study
0.26
7.42
7.68
5.13.3.1.33 Transerrin (biochemical blood test)* Study
0.26
5.92
6.18
5.13.3.1.34 Mioglobin (biochemical blood test)* Study
0.26
16.61
16.87
5.13.3.1.35 Microalbumin in the urine* Study
0.26
4.44
4.70
5.13.3.1.36 Magnesium (biochemical blood test)* Study
0.26
0.66
0.92
5.13.3.1.37 Apoprotein A1 (biochemical blood test)* Study
0.26
6.49
6.75
5.13.3.1.38 Apoprotein B (biochemical blood test)* Study
0.26
6.05
6.31
5.13.3.1.41 Copper (biochemical blood test)* Study
0.26
3.57
3.83
5.13.3.1.42 Alpha - 1 - antitripsin (biochemical blood test) Study
0.26
14.46
14.72
5.13.3.1.43 Cerulloplasmin (biochemical blood test)* Study
0.26
7.37
7.63
5.13.3.1.44. Glucose (glucosotolerant test - GTT) 2 -multiple Study
0.26
7.90
8.16
5.13.3.1.46 Fructosamine Study
0.26
4.90
5.16
5.13.3.1.47 Tsistatin C* Study
0.26
9.94
10.20
5.13.3.1.50 General iron -binding capacity (OHSSS, UIBC)* Study
0.26
6.77
7.03
5.2. Biochemical studies using photoelectrocolorimeters and single -channel biochemical automatic filmmers 5.2.7. Determination of glucose in solid blood express method Study
1.14
2.15
3.29
5.6. Biochemical studies The determination of indicators of the acid-base state of the blood through automatic analyzers 5.6. Determination of indicators of the acid-base state (COST) Study
0.93
30.86
31.79
5.6.1. Determination of indicators of the acid-base state of the blood through automatic analyzers (KSHS) Study
0.93
30.88
31.81
5.9.1. Determination of hormones by immuno -function analysis with automated calculation 5.9.1.1 Estradiol (determination of sex hormones) * Study
1.14
8.03
9.17
5.9.1.1.2 Follicle -stimulating hormone (FSH) (determination of sex hormones) FG* Study
1.14
7.83
8.97
5.9.1.1.3 Luteinizing hormone (determination of sex hormones) LH* Study
1.14
11.18
12.32
5.9.1.1.4. Progesterone (determination of sex hormones) Study
1.14
8.03
9.17
5.9.1.1.5 Prolactin (determination of sex hormones) PLN* Study
1.14
11.65
12.79
5.9.1.1.6. Testosterone (determination of sex hormones) TCTN* Study
1.14
14.26
15.40
5.9.1.1.7. Chorionic gonadotropin or its beta-bomb (determination of sex hormones) hCG or B-hCCH* Study
1.14
9.50
10.64
5.9.1.1.8. Tireotropic hormone (TSH) (determination of hormones, thyroid gland) TTG* Study
1.14
7.44
8.58
5.9.1.1.9. Free thyroxine (determination of hormones, thyroid gland) ft4* Study
1.14
5.32
6.46
5.9.1.1.10. Free triiodothyronine (determination of hormones, thyroid gland) FT3* Study
1.14
6.52
7.66
5.9.1.1.11. Prokalcitonin (determination of hormones, other) PCCN Study
1.14
47.18
48.32
5.9.1.1.12. Cortisol (determination of hormones, other) KRL Study
1.14
21.06
22.20
5.9.1.1.13. Anti -TG antibodies to tyroglobulin (determination of hormones, thyroid gland) anti -TG* Study
1.14
9.88
11.02
5.9.1.1.14. DGEA -I4 Study
1.14
26.00
27.14
5.9.1.1.15. 17-ON progesterone Study
1.14
7.32
8.46
5.9.1.1.16. Determination of parathormone Study
1.14
9.22
10.36
5.9.1.2.2. Antibodies antibodies to thyrooperoxidase (determination of hormones, thyroid gland)* Study
1.45
14.47
15.92
6. Studies of hemostasis 6.6.4. Determining the content of fibrinogen in plasma on an automatic coagulometer* Study
0.26
6.85
7.11
6.31. Determination of the lupus anticoagulant by the clotting method* Study
6.96
26.88
33.84
6.34. Determination of antitrombin III (AT III) Study
4.05
26.24
30.29
6.37. Determination of protein with an automatic coagulometer Study
3.88
31.52
35.40
6.38. Determination of protein S on an automatic coagulometer Study
3.88
54.74
58.62
6.39. Determination of D-Dimers* Study
4.05
22.59
26.64
6.39.1. Determination of D-Dimers with an express method (immunofluorescent analysis) Study
4.05
20.26
24.31
6.40.1. Determination of activated partial thromboplastin time on an automatic coagulometer (ACTVT)* Study
0.26
3.72
3.98
6.40.2. Determination of prothrombin time (PTV) with thromboplastin calcium mixture with the calculation of many Study
0.26
12.47
12.73
6.40.2.1. Determination of prothrombin time (PTV) with the calculation of many - express tests from capillary blood (finger)* Study
0.26
8.00
8.26
6.40.3. Determination of thrombin time (TV) Study
0.26
6.16
6.42
6.40.4 Determination of anti-ha hemostasis factor Study
0.26
22.86
23.12
7. Immunological studies 7.2. Determination of blood groups according to the AVO system in the cross, determination of the Rh factor Study
1.66
6.87
8.53
7.4. Determination of incomplete Rhesus antibodies by conglutination Study
6.76
1.65
8.41
7.6. Direct Cumbsa test Study
7.80
2.23
10.03
7.7. Indirect sample of kumbs Study
13.52
5.27
18.79
7.16.2.1. SRB General (determination of individual blood serum proteins with a turbidimetric method)* Study
0.52
4.04
4.56
7.16.2.2. SRB is ultra -sensitive (determination of individual blood serum proteins with a turbidimetric method) Study
0.52
2.67
3.19
7.16.2.3 Immunoglobulin a* Study
0.52
5.11
5.63
7.16.2.4 Immunoglobulin m* Study
0.52
5.30
5.82
7.16.2.5 Immunoglobulin g* Study
0.52
5.30
5.82
7.16.2.6 Immunoglobulin e* Study
1.04
13.97
15.01
7.17.2. Determining the activity of anti -o - o - streptolizine in blood serum latex test* Study
0.39
4.43
4.82
7.19.2.1.1. Determination of autoantiber towards class M cardiolipin (IGM) by immuno -function analysis, semi -automated calculation Study
1.04
12.31
13.35
7.19.2.1.2. Determination of autoantibodies to class G (IgG) cardiolipin method by immunoformal analysis, semi -automated calculation Study
1.04
12.31
13.35
7.19.2.1.3. Determination of autoantiber to beta 2-glycoprotein class M (IGM) by immuno-function analysis, semi-automated calculation Study
1.04
12.31
13.35
7.19.2.1.4. Determination of autoantiber towards beta2-glycoprotein class G (IgG) by immunofortment analysis, semi-automated calculation Study
1.04
12.31
13.35
7.19.2.1.5. Determination of autoantibodies to nucleosomes by immuno -function analysis, semi -automated calculation* Study
1.04
12.91
13.95
7.19.2.1.6. Determination of autoantel to double-chain DNA (DS-DNA)* Study
1.04
12.34
13.38
7.19.2.1.7. Determination of antinuclear antibodies (ANA)* Study
1.04
12.34
13.38
7.19.2.1.8. Determination of anticytoplasmic antibodies (anca) Study
1.04
12.34
13.38
7.19.2.1.9. Determination of antibodies to cyclical citrulinated peptide (ACCP)* Study
1.04
14.59
15.63
7.19.2.1.10 Determination of autoantibodies to mitochondria (ama) Study
1.04
12.29
13.33
7.19.2.1.11 Determination of autoantibodies to tissue transglutaminase IG A Study
1.04
11.70
12.74
7.19.2.1.12 Determination of autoantiber to tissue transglutaminase IG G Study
1.04
12.28
13.32
7.19.2.1.13. Determination of antibodies to a modified citrulinized viementin (MCV)* Study
1.04
17.75
18.79
7.19.2.1.14. Determination of the rheumatoid factor IG M Study
1.04
12.28
13.32
7.19.2.1.15 Determination of autoantibodies to myeloperoxidase (MRO) Study
1.04
12.25
13.29
7.19.2.1.16 Determination of autoantiber to proteinase-3 (PR-3) Study
1.04
13.65
14.69
7.19.2.1.17. Determination of autoantibodies to the internal factor (KALEA) Study
1.04
12.97
14.01
7.19.2.1.18. Determination of antibodies to gliadin IG A (Anti-Gliadin Iga) Study
1.04
12.05
13.09
7.19.2.1.19. Determination of antibodies to gliadin IG G (Anti-Gliadin IgG) Study
1.04
12.05
13.09
7.19.2.1.20. Determination of antibodies to Saccaharomyces Cerevisiae A (ASCA IG A) Study
1.04
12.05
13.09
7.19.2.1.21. Definition of antibodies to Saccaharomyces Cerevisiae G (ASCA IG G) Study
1.04
12.05
13.09
7.19.2.1.22. Screening of antiphospholipid total antibodies (AT to cardiolipin, beta-2-glycoprotein-1, phosphotydilositol, phosphotididserin) class M Anti-Phospholipid Screen IgM* Study
1.04
12.05
13.09
7.19.2.1.23. Screening of antiphospholipid total antibodies (AT to cardiolipin, beta-2-glycoprotein-1, phosphotydilositol, phosphotididserin) class G Anti-Phospholipid Screen igg* Study
1.04
12.25
13.29
7.19.2.1.24. Determination of antibodies to phosphotylserin class m (AT to phosphotidylserin IG M) Study
1.04
12.00
13.04
7.19.2.1.25. Determination of antibodies to phosphotylserin class G (AT to phosphotidylserin IG G) Study
1.04
12.00
13.04
7.19.2.1.26. Determination of antibodies to Latoferrin (at-K Lacterrin) Study
1.04
10.07
11.11
7.19.2.1.27. Determination of antibodies to a soluble liver antigen (anti-sla) Study
1.04
15.17
16.21
7.19.2.1.28. Determination of antibodies to the microsomes of the liver and kidneys (Anti-LKM-1) Study
1.04
15.15
16.19
7.19.2.1.29. Determination of antibodies to the deaminated peptide of gliadine IG A (anti-dgp ig a) Study
1.04
12.19
13.23
7.19.2.1.30. Determination of antibodies to the deaminated peptide of gliadine Ig G (anti-dgp ig g) Study
1.04
12.19
13.23
7.19.2.1.31. Determination of antibodies to the parietal cells of the stomach IG G (anti-Parietal Cell IgG) Study
1.04
12.24
13.28
7.19.2.1.32. Determination of antibodies to the basal membrane of the Bloons IG G (Anti-GBM IgG) Study
1.04
13.70
14.74
7.19.2.1.33. Determination of antibodies (high-quality) ANA-immunoblotting class 9 parameters Study
1.04
32.75
33.79
7.19.2.1.34. Determination of antibodies (high -quality) -Miosite profile -immunoblotting Study
1.04
32.75
33.79
7.19.2.1.35. Determination of antibodies (high -quality) -anca profile -immunoblotting 3 parameters Study
1.04
32.75
33.79
7.19.2.1.36. Determination of vitamin D2/d3-OH* Study
1.04
35.66
36.70
7.19.2.1.37. Determination of antibodies (high-quality) class ANA-Immunoblotting17 parameters Study
1.04
45.70
46.74
7.19.2.1.38. Insulin definition* Study
1.04
9.10
10.14
7.19.2.1.39. Determination of vitamin in 12* Study
1.04
15.23
16.27
7.19.2.1.40. Determination of pyrilinks-D (bone resorption marker) Study
1.04
44.18
45.22
7.19.2.1.41 Determination of osteocalcine Study
1.04
19.65
20.69
7.19.2.1.42 Determination of the level of folates (vitamin B9, folic acid)* Study
1.04
20.62
21.66
7.19.2.1.45 Determination of ELISA ANTI-SS-A (Reve.) Study
1.04
19.26
20.30
7.19.2.1.46 Determination of ELISA ANTI-SS-B (Reve.) Study
1.04
19.26
20.30
7.19.2.1.47 Determination of ELISA ANTI-SM (Reve.) Study
1.04
19.26
20.30
7.19.2.1.48 Determination of ELISA ANTI-SS-A 52 (Reve.) Study
1.04
19.26
20.30
7.19.2.1.49 Determination of ELISA ANTI-SS-A 60 (Reve.) Study
1.04
19.26
20.30
7.19.2.1.50 Definition of Anti-Rnp/SM ELIS (Reve.) Study
1.04
19.26
20.30
7.19.2.1.51 Determination of ELISA Anti-SCL-70 (Reve.) Study
1.04
19.26
20.30
7.19.2.1.52 Determination of ELISA ANTI-CENTROMERE B (Reve.) Study
1.04
19.26
20.30
7.19.2.1.53 Determination of ELISA ANTI-JO-1 (Reve.) Study
1.04
19.26
20.30
7.21.2. Rheumatoid factor (determination in the blood serum with a latex test)* Study
0.39
3.22
3.61
8. Bacteriological studies 8.3.1. Microscopy of stained (according to gram) drugs of native material, sputum, flushing waters of the bronchi, transudates, exudates (studies on aerobic and optional anaerobic microorganisms) Study
3.43
0.49
3.92
8.17.9.1.1. Determination of antigens to Helicobacter pylori in feces (to viral and bacterial antigens method by immunofortment analysis with semi -automated calculations) Study
3.43
11.66
15.09
8.17.9.1.2. Determination of antibodies to Helicobacter pylori in the blood (to viral and bacterial antigens method by immunofortment analysis with semi -automated calculation) Study
3.43
5.10
8.53
8.17.9.1.3. Determination of antibodies (IgG) to the Varicella Zoster virus (to viral and bacterial antigens by immuno -function analysis with semi -automated calculations) Study
3.43
6.59
10.02
8.17.9.1.4. Determination of antibodies (IgM) to toxoplasm* Study
3.43
7.04
10.47
8.17.9.1.5. Determination of antibodies (IgG) to toxoplasm* Study
3.43
7.80
11.23
8.17.9.1.6. Determination of antibodies to cytomegalovirus (IgM CMV)* Study
3.43
6.35
9.78
8.17.9.1.7. Determination of antibodies to cytomegalovirus (IgG CMV)* Study
3.43
6.26
9.69
8.17.9.1.8. Determination of IgG to the early capsid antigen of the Epstein Barra virus (EBV VCA/EA IgG) Study
3.43
10.05
13.48
8.17.9.1.9. Determination of IGM to the capsid antigen of the Epstein Barra virus (EBV VCA IgM) Study
3.43
10.05
13.48
8.17.9.1.10. Determination of IgG to the nuclear antigen of the Epstein Barra virus (EBV Ebna IgG) Study
3.43
9.40
12.83
8.17.9.1.11. Screening test for determining syphilis (RPR-Carbon) Study
3.43
5.43
8.86
8.17.9.1.12. Determination of antibodies (IgG) to the hepatitis C virus (Anti-HCV)* Study
3.43
17.23
20.66
8.17.9.1.13. Determination of high -quality superficial antigen of the hepatitis B (HBS AG Ultra)** Study
3.43
16.57
20.00
8.17.9.1.14 Determination of antibodies (IgM) to rubella (Rubella)* Study
3.43
6.63
10.06
8.17.9.1.15 Determination of antibodies (IG G) to rubella (Rubella)* Study
3.43
7.03
10.46
8.17.9.1.16 Determination of antibodies (IGM) to the herpes simplex virus type 1/2* Study
3.43
17.25
20.68
8.17.9.1.17 Determination of antibodies (IgG) to the herpes simplex virus type 1/2* Study
3.43
13.84
17.27
8.17.9.1.18. Determination of IGG Avity to cytomegalovirus Study
3.43
26.66
09.30
8.17.9.1.19 Determination of IGG Avil to toxoplasm* Study
3.43
18.78
22.21
8.17.9.1.20 Determination of antibodies (IG G) to AT to Chlamydia pneumoniae in serum Study
3.43
05/17
20.48
8.17.9.1.21 Determination of antibodies (Ig a) to Mycoplasma Study
3.43
14.30
17.73
8.17.9.1.22 Determination of antibodies (IG M with absorption) to AT to Mycoplasma Pneumoniae in serum Study
3.43
17.18
20.61
8.17.9.1.23 Determination of antibodies (IG G) to Mycoplasma pneumoniae in serum Study
3.43
14.30
17.73
8.17.9.1.24 Determination of antibodies (IG A) to at AT to Chlamydia pneumoniae in serum Study
3.43
19.40
22.83
8.17.9.1.25 Determination of antibodies (IG m with absorption) to AT to Chlamydia pneumoniae in serum Study
3.43
20.75
24.18
8.17.9.1.26 Determination of antibodies (m, g) to Sars-Cov-2 in the blood Study
3.43
11.72
15.15
8.17.9.4.1. Determination of immunoglobulins (antibodies) of one class to chlamydia Trachomatis (IG G) with manual calculation of the positiveness coefficient and antibodies titer* Study
3.53
15.98
19.51
8.17.9.4.2. Determination of immunoglobulins (antibodies) of one class to chlamydia Trochomatis (IG A) with manual calculation of the positiveness coefficient and antibodies titer* Study
3.53
15.92
19.45
8.17.9.4.3. Determination of immunoglobulins (antibodies) of one class to chlamydia Trochomatis-IGM (with the absorbent of the Russian Federation)* procedure
3.53
19.36
22.89
9. Genetic studies 9.7. Looping tests with glucose (glucosotolerant test-GGT 2 multiple) Study
2.62
1.64
4.26
- Determining the number of IGG/IgM antibodies to SARS-COV-2 method (FIA) for citizens of the Republic of Belarus
The cost is represented in Belarusian rubles.
Name of the service Unit of measurement Rate
No VATThe cost of supplies Total cost 1
2
3
4
5
6
1. 2. Registration (preliminary and final) of the material, patient’s passport data and research results in journals and banks or PC GCT* Study
0.59
0.50
1.09
1. 2. 1. Registration (provision of results by e -mail)* Study
0.59
0
0.59
*1 Determination of antibodies to the Covid virus using the ICHROMA analyzer GCT* Study
7.27
19.58
26.85
1. 3. 1. Taking blood from a finger (antibodies GCT) Study
0.24
1.57
1.81
- Quantitative determination of IgG antibodies to the SARS-COV-2 virus
The cost is represented in Belarusian rubles.
Name of the service Unit of measurement Rate
No VATThe cost of supplies Total cost 1
2
3
4
5
6
2 ** Quantitative determination of IgG antibodies to the SARS-COV-2 virus Study
10.13
23.83
33.96
1. Separate operations 1. 2. * Registration (preliminary and final) of the material, patient’s passport data and research results in journals and banks or PCs* Registration
2.66
0.50
3.16
1.4. Vienna 1. 4. * Blood sampling from a vein (biochemical blood test, UAC)* Study
2.56
1.08
3.64
1. 5. Celent blood processing to obtain plasma or serum* Study
1.76
0.02
1.78
1. 2. 1. Registration (provision of results by e -mail)* Study
2.66
0
2.66
ВНИМАНИЕ! В связи с техническими работами на сайте, возможно некорректное отображение информации.
Администрация больницы приносит свои извинения!
Contacts
Head Physician's RECEPTION +375 17 221-14-24 Mon-Fri 8.30 - 17.00
PHONE FOR PAID SERVICES: +375 17 377-09-37 +375 29 394-67-94 Mon-Fri 8.30 - 16.15
THERAPY CENTER +375 17 245-10-01 Mon-Sun 8.00-20.00 seven days a week
TRAUMATOLOGY Help Desk: +375 17 398-86-43 +375 29 126-26-47 Mon-Sun 8.00-20.00
HOTLINE Phone: +375 17 392-54-68 Mon-Fri 8.30 - 17.00
MATERNITY HOSPITAL EMERGENCY OFFICE: +375 17 245-18-31 24/7
«TRUST PHONE»: +375 17 385-94-42 24/7
NARCOLOGICAL SERVICE of Minsk: 183 Single number +375(29) 149-09-09 (A1) +375(17) 357-09-09
uz@6gkb.by
5, Uralska Street, Minsk, 220037
phone: +375 (17) 221-14-24 (reception)
fax: +375 (17) 245-26-21
Internet resources
© 2025 Healthcare institution "6th city clinical hospital of Minsk"